We advised the bookrunners on the offering

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the offering by Amgen Inc. of $1 billion aggregate principal amount of 4.200% senior notes due 2031, $1.75 billion aggregate principal amount of 4.850% senior notes due 2036, $500 million aggregate principal amount of 5.500% senior notes due 2046 and $750 million aggregate principal amount of 5.650% senior notes due 2056.

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. Amgen helped launch the biotechnology industry more than 40 years ago and has grown to be one of the world’s leading independent biotechnology companies. Its robust pipeline includes potential first-in-class medicines at all stages of development.

The Davis Polk corporate team included partner Roshni Banker Cariello and associate Marcos Sauquet Trias. Counsel Liang Zhang and associate Zoey Chau provided tax advice. Partner David R. Bauer and associates Elizabeth Pott and Hannah Coleman provided intellectual property advice. Members of the Davis Polk team are based in the New York and Northern California offices.

Copy link to share post